|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0582 - 0.0582|
|52 Week Range||0.0510 - 0.9020|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 10, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.78|
HALIFAX, Nova Scotia, June 29, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.
HALIFAX, Nova Scotia, May 26, 2022--Appili Therapeutics Inc. (TSX: APLI) (the "Company" or "Appili") announced the closing of its previously announced public offering (the "Offering") of units (the "Units"). The Offering was made pursuant to an agency agreement, as amended, entered into between the Company, Bloom Burton Securities Inc. (the "Lead Agent") and Leede Jones Gable Inc. (collectively with the Lead Agent, the "Agents").